Supernus, Inc. (SUPN)

Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$28.61+0.92%As of 2026-11-22 · USD
Last session low $28.15Last session high $29.51
52-week low $25.9252-week high $42.81
Market cap
$5.94B
Sector
Healthcare

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-19 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in USD.

IndicatorValueReading
RSI (14)29.9In the oversold range (below 30)
MACD (12, 26, 9)-3.27Level with its signal line (-3.26)
Bollinger %B (20, 2)33%Inside the bands (20.48 to 45.36)
SMA 2032.92Price is 13.1% below
SMA 5038.43Price is 25.6% below
SMA 20045.90Price is 37.7% below
ATR (20)6.64% of priceAverage true range per day
52-week position16%In the lower part of the 25.92 to 42.81 range

About Supernus, Inc.

Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.

Insider filings, 90 days1 purchase (about $54K) and no sales.
Latest fiscal yearEnded 2025-12-31: revenue of $718.95M and an operating margin of -5.1%.

More in Drug Manufacturers - Specialty & Generic